

COPY OF PAPERS
ORIGINALLY FILED



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/534,706
		Filing Date	March 23, 2000
		First Named Inventor	Ellman, Jonathan A.
		Art Unit	1624
		Examiner Name	T. McKenzie
		Attorney Docket Number	18062G-002010
Sheet	1	of	1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JCN	1	CATALDO, et al., "Colocalization of Lysosomal Hydrolase and β -Amyloid in Diffuse Plaques of the Cerebellum and Striatum in Alzheimer's Disease and Down's Syndrome," <i>Journal of Neuropathology and Experimental Neurology</i> , 55(6):704-715 (1996)	
	2	CATALDO, et al., "Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain," <i>Proc. Natl. Acad. Sci. USA</i> , 87:3861-3865 (1990)	
	3	CATALDO, et al., "Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease," <i>Medical Sciences</i> , 88:10998-11002 (1991)	
	4	CATALDO, et al., "Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin," <i>Brain Research</i> , 513:181-192 (1990)	
	5	HAQUE, et al., "Potent, Low-Molecular-Weight Non-Peptide Inhibitors of Malarial Aspartyl Protease Plasmepsin II," <i>J. Med. Chem.</i> , 42:1428-1440 (1999)	
	6	Li, et al., "Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and Senile dementia and in the aged," <i>Virchows Archiv A Pathol Anat</i> , 423:185-194 (1993)	
	7	KREUTZBERG, Microglia, the First Line of Defence in Brain Pathologies," <i>Arzneim.-Forsch./Drug Res.</i> 45(1), Nr. 3a, 357-360 (1995)	
	8	LEE, et al., "General Solid-Phase Synthesis Approach To Prepare Mechanism-Based Aspartyl Protease Inhibitor Libraries. Identification of Potent Cathepsin D Inhibitors," <i>J. Am. Chem. Soc.</i> , 120:9735-9747 (1998)	

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

Examiner Signature	<i>Tom McLaughlin</i>	Date Considered	12/17/02
--------------------	-----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9043679 v1